Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement

American Journal of Surgical Pathology

Volumn 36, Issue 10, 2012, Pages 1562-1570

  Lee, Cheng Han ^a,b   Ali, Rola H ^a,b   Rouzbahman, Marjan ^d   Marino Enriquez, Adrian ^a   Zhu, Meijun ^a   Guo, Xiangqian ^f   Brunner, Alayne L ^f   Chiang, Sarah ^e   Leung, Samuel ^a,b   Nelnyk, Nataliya ^c   Huntsman, David G ^c   Blake Gilks, C ^a,b   Nielsen, Torsten O ^a,b   Cin, Paola Dal ^a   Van De Rijn, Matt ^f   Oliva, Esther ^e   Fletcher, Jonathan A ^a   Nucci, Marisa R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cyclin D1; endometrial stromal sarcoma; JAZF1 SUZ12; uterine sarcoma; YWHAE FAM22

Indexed keywords

CCND1 PROTEIN, HUMAN; CYCLIN D1; ONCOPROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; SUZ12 PROTEIN, HUMAN; TUMOR MARKER; YWHAE FAM22 FUSION PROTEIN, HUMAN; YWHAE-FAM22 FUSION PROTEIN, HUMAN;

ARTICLE; CELL NUCLEUS; ENDOMETRIUM SARCOMA; ENDOMETRIUM TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; HUMAN; LEIOMYOSARCOMA; METABOLISM; PATHOLOGY; TISSUE MICROARRAY; UPREGULATION;

CELL NUCLEUS; CYCLIN D1; ENDOMETRIAL NEOPLASMS; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEIOMYOSARCOMA; ONCOGENE PROTEINS, FUSION; POLYCOMB REPRESSIVE COMPLEX 2; SARCOMA, ENDOMETRIAL STROMAL; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84866630961     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31825fa931     Document Type: Article

References (40)

1. Chiang S, Ali R, Melnyk N, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35:1364-1372.
2. Huang HY, Ladanyi M, Soslow RA. Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneity. Am J Surg Pathol. 2004;28:224-232.
3. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA. 2001;98:6348-6353.
4. Micci F, Panagopoulos I, Bjerkehagen B, et al. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66:107-112.
5. Nucci MR, Harburger D, Koontz J, et al. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol. 2007;31:65-70.
6. Oliva E, de Leval L, Soslow RA, et al. High frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with smooth muscle differentiation by interphase FISH detection. Am J Surg Pathol. 2007;31:1277-1284.
7. Sandberg AA. The cytogenetics and molecular biology of endome-trial stromal sarcoma. Cytogenet Genome Res. 2007;118:182-189.
8. Lee CH, Ou WB, Marino-Enriquez A, et al. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA. 2012;109:929-934.
9. Lee CH, Marino-Enriquez A, Ou WB, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36:641-653.
10. Sjoquist KM, Martyn J, Edmondson RJ, et al. The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer. 2011;21:1328-1333.
11. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopatho-logy. 2009;54:355-364.
12. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32:1228-1238.
13. Lee CH, Espinosa I, Vrijaldenhoven S, et al. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008;14:1423-1430.
14. Lee CH, Turbin DA, Sung YC, et al. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol. 2009;22:1519-1531.
15. Tusher VG, Tibshirani R, Chu G. Significance analysis of micro-arrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-5121.
16. Kurihara S, Oda Y, Ohishi Y, et al. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol. 2010;23:225-234.
17. de Jong RA, Nijman HW, Wijbrandi TF, et al. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol. 2011;24:1368-1379.
18. Kanthan R, Senger JL, Diudea D. Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins. World J Surg Oncol. 2010;8:60.
19. Dionigi A, Oliva E, Clement PB, et al. Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2002;26: 567-581.
20. Oliva E, Young RH, Clement PB, et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol. 1999;18:310-319.
21. Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002;26:1142-1150.
22. Andino L, Cagle PT, Murer B, et al. Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression. Arch Pathol Lab Med. 2006;130:1503-1509.
23. Dei Tos AP, Piccinin S, Doglioni C, et al. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151:1531-1539.
24. Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155:1885-1891.
25. Takahashi Y, Oda Y, Kawaguchi K, et al. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdo-myosarcoma. Mod Pathol. 2004;17:660-669.
26. Nakamura N, Yamamoto H, Yao T, et al. Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 2005;36:828-837.
27. Leunen K, Amant F, Debiec-Rychter M, et al. Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecol Oncol. 2003;91:265-271.
28. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res. 2004;10:1344-1353.
29. Amant F, Tousseyn T, Coenegrachts L, et al. Case report of a poorly differentiated uterine tumour with t(10;17) translocation and neuroectodermal phenotype. Anticancer Res. 2011;31:2367-2371.
30. Blattner JM, Gable P, Quigley MM, et al. Primitive neuro-ectodermal tumor of the uterus. Gynecol Oncol. 2007;106:419-422.
31. Sinkre P, Albores-Saavedra J, Miller DS, et al. Endometrial endome-trioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor. Int J Gynecol Pathol. 2000;19:127-132.
32. Taieb S, Cabaret V, Bonodeau F, et al. MRI of primitive neuroectodermal tumor of the uterus. J Comput Assist Tomogr. 1998;22:896-898.
33. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726-2732.
34. Yang WI, Zukerberg LR, Motokura T, et al. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol. 1994;145:86-96.
35. Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol. 2011;28:245-255.
36. Williams ME, Swerdlow SH. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann Oncol. 1994;5(suppl 1):71-73.
37. Hong A, Davies S, Stevens G, et al. Cyclin D1 overexpression in AIDS-related and classic Kaposi sarcoma. Appl Immunohistochem Mol Morphol. 2004;12:26-30.
38. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 2006;130:792-798.
39. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol. 2009;220:292-296.
40. Lin L, Hicks D, Xu B, et al. Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma. Mod Pathol. 2005;18:705-709.